Trial intelligence / Profile preview

Hydroxynitron capsules for chronic hepatitis B liver fibrosis (Phase IIIc)

CTR20260328Phase 3Active

Sponsor
Gyre Pharmaceuticals
Start
Mar 2026
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of hydronidone in Chronic Hepatitis B (CHB), hepatic fibrosis, sponsored by Gyre Pharmaceuticals. Started Mar 2026; status: active.

02

Drugs

hydronidone
03

Conditions

Chronic Hepatitis B (CHB)hepatic fibrosis

Beyond the preview

Go deeper on CTR20260328.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20260328.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call